Therapeutic approaches of cocaine addiction;Une approche thérapeutique combinée dans l'addiction à la cocaïne

Revue du Praticien

Volumn 59, Issue 6, 2009, Pages

  Karila, Laurent ^a   Reynaud, Michel ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMFEBUTAMONE; AMISULPRIDE; ANTIDOTE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; DEXAMPHETAMINE; DISULFIRAM; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; GABAERGIC RECEPTOR AFFECTING AGENT; HALOPERIDOL; METHADONE; METHYLPHENIDATE; MODAFINIL; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PARACETAMOL; PARTIAL AGONIST; RISPERIDONE; TIAGABINE; TOPIRAMATE; VACCINE;

BRAIN; CLINICAL TRIAL; COCAINE DEPENDENCE; DRUG DETOXIFICATION; DRUG EFFICACY; DRUG TOLERANCE; EUPHORIA; GENETICS; HUMAN; IDIOPATHIC DISEASE; NARCOLEPSY; NEUROBIOLOGY; NEUROIMAGING; NEUROPSYCHOLOGY; PATHOPHYSIOLOGY; PSYCHOTHERAPY; RELAPSE; RESEARCH; REVIEW; SUBSTITUTION THERAPY; WITHDRAWAL SYNDROME;

COCAINE-RELATED DISORDERS; DOPAMINE UPTAKE INHIBITORS; GABA AGONISTS; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 67649971491     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Gass JT, Olive MF. Glutamatergic substrates of drug addiction and alcoholism. Biochem Pharmacol 2008;75:218-265 (Pubitemid 350235390)
2. LaRowe SD, Mardikian P, Malcolm R, et al. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict 2006;15:105-110 (Pubitemid 43207196)
3. LaRowe S, Myrick H, Hedden SL, et al. Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry 2007;164:1115-1117
4. Mardikian PN, Larowe SD, Hedden S, Kalivas PW, Malcolm RJ. An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: a pilot study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31.
5. Karila L, Weinstein A, Benyamina A, et al. Pharmacothérapies actuelles et immunothérapie dans l'addiction a la cocaïne. Presse Med 2008;37:689-698
6. Ballon JS, Feifel D. A systematic review of modafinil: Potential clinical uses and mechanisms of action. J Clin Psychiatry 2006;67:554-566 (Pubitemid 43764232)
7. Ferraro L, Antonelli T, O'Connor WT, Tanganelli S, Rambert F, Fuxe K. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1997;8:2883-2887 (Pubitemid 27394812)
8. Dopheide M, Morgan R, Rodvelt K, Schachtman T, Miller D. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007;568:112-123
9. Zolkowska D, Jain R, Rothman RB, et al. Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 2009;329:738-746
10. Volkow ND, Fowler JS, Logan J, et al. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009;301:1148-1154
11. Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000;14:53-60. (Pubitemid 30156539)
12. Jasinski DR, Kovacevic-Ristanovic R. Evaluation of the abuse liability of modafinil and other drugs for excessive daytime sleepiness associated with narcolepsy. Clin Neuropharmacol 2000;23:149-156 (Pubitemid 30395376)
13. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005;30:205-211
14. Hart CL, Haney M, Voburg SK, Rubin E, Foltin RW. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008;33:761-768
15. Donovan JL, DeVane CL, Malcolm RJ, et al. Modafinil influences the pharmacokinetics of intravenous cocaine in healthy cocaine-dependent volunteers. Clin Pharmacokinet 2005;44:753-765 (Pubitemid 40994083)
16. Malcolm R, Swayngim K, Donovan J, et al. Modafinil and cocaine interactions. Am J Drug Alcohol Abuse 2006;32:577-587 (Pubitemid 44870996)
17. Elkashef A, Vocci JF. Promising medications for the treatment of cocaine addiction. Presented at American Psychiatric Association annual meeting. San Diego, CA, 2007.
18. Turner DC, Robbins TW, Clark L, Aron AR, Dowson J, Sahakian BJ. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003;165:260-269 (Pubitemid 36197601)
19. Karila L, Reynaud M. Addiction à la cocaïne. Paris, Flammarion Médecine-Sciences éd., 2009.
20. Vocci FJ, Elkashef A. Pharmacotherapy and other treatments for cocaine abuse and dependence. Curr Opin Psychiatry 2005;18:265-270 (Pubitemid 40586109)
21. Sofuoglu M, Kosten TR. Novel approaches to the treatment of cocaine addiction. CNS Drugs 2005;19:13-25. (Pubitemid 40165154)
22. Ait Daoud N, Johnson B. Open-label trial of topiramate for treating cocaine dependence. Presented at the College on Problem of Drug Dependence annual meeting. San Juan, 2004, Jun 13.
23. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend 2004;75:233-240 (Pubitemid 38993293)
24. Ling W, Shoptaw S, Majewska D. Baclofen as a cocaine anti-craving medication: a preliminary clinical study. Neuropsychopharmacology 1998;18:403-404 (Pubitemid 28140667)
25. Brebner K, Childress AR, Roberts DC. A potential role for GABA(B) agonists in the treatment of psychostimulant addiction. Alcohol Alcohol 2002;37:478-484
26. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry 2003;64:1440-1448 (Pubitemid 41270102)
27. Kahn R, Biswas K, Childress AR, et al. Multi-center trial of baclofen for abstinence initiation in severe cocaine-dependent individuals. Drug Alcohol Depend 2009;103:59-64.
28. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005;55:122-125 (Pubitemid 39665670)
29. Sofuoglu M, Kosten TR. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin Emerg Drugs 2006;11:91-98
30. Gonzalez G, Sevarino K, Sofuoglu M, et al. Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study. Addiction 2003;98:1625-1632 (Pubitemid 37373861)
31. Winhusen TM, Somoza EC, Harrer JM, et al. A placebo-controlled screening trial of tiagabine, sertraline and donepezil as cocaine dependence treatments. Addiction 2005;100:68-77. (Pubitemid 40363426)
32. Gonzalez G, Desal R, Sofuoglu M, et al. Clinical efficacy of gabapentin versus tiagabine for reducing cocaine use among cocaine dependent methadone-treated patients. Drug Alcohol Depend 2007;87:1-9. (Pubitemid 46074378)
33. Reid MS, Casadonte P, Baker S, et al. A placebo-controlled screening trial of olanzapine, valproate, and coenzyme Q10/L-carnitine for the treatment of cocaine dependence. Addiction 2005;100:43-57. (Pubitemid 40363424)
34. Suh JJ, Pettinati HM, Kampman KM, O'Brien CP. The status of disulfiram: a half of a century later. J Clin Psychopharmacol 2006;26:290-302. (Pubitemid 43804621)
35. Malcolm R, Olive MF, Lechner W. The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opin Drug Saf 2008;7:459-472
36. Vocci F, Ling W. Medications development: successes and challenges. Pharmacol Ther 2005;108:94-108. (Pubitemid 41377122)
37. Gossop M, Carroll KM. Disulfiram, cocaine, and alcohol: two outcomes for the price of one? Alcohol Alcohol 2006;41:119-120
38. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F. Disulfiram therapy in patients abusing cocaine and alcohol. Am J Psychiatry 1993;150:675-676 (Pubitemid 23109948)
39. Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL, Rounsaville BJ. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 2000;95:1335-1349 (Pubitemid 30707678)
40. Carroll KM, Nich C, Ball SA, McCance E, Rounsavile BJ. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 1998;93:713-727 (Pubitemid 28230603)
41. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry 2004;61:264-272 (Pubitemid 38295828)
42. Pettinati HM, Kampman KM, Lynch KG, et al. A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence. Addict Behav 2008;33:651-667
43. George TP, Chawarski MC, Pakes J, Carroll KM, Kosten TR, Schottenfeld RS. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry 2000;47:1080-1086 (Pubitemid 30336217)
44. Amato L, Minozzi S, Pani P, Davoli M. Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev 2007;3:CD006306. (Pubitemid 351805438)
45. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia: Systematic review. Br J Psychiatry 2006;189:102-108 (Pubitemid 44231267)
46. Beresford TP, Clapp L, Martin B, Wiberg JL, Alfers J, Beresford HF. Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol 2005;25:363-366 (Pubitemid 41060257)
47. Vorspan F, Bellais L, Kleijzer L, Lepine J. An Open-Label Study of Aripiprazole in nonschizophrenic crack dependent patients. J Clin Psychopharmacol 2008;28:570-572
48. Margolin A, Kosten TR, Avants SK, et al. A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. Drug Alcohol Depend 1995;40:125-131 (Pubitemid 26011975)
49. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry 2006;63:219-228 (Pubitemid 43213884)
50. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drag Alcohol Depend 2007;87:20-29
51. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 2001;21:522-526 (Pubitemid 32937435)
52. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 2004;29:969-981 (Pubitemid 38526797)
53. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. Addiction 2003;98:1137-1141 (Pubitemid 36936500)
54. Vansickel AR, Fillmorex MT, Hays LR, Rush CR. Effects of potential agonist-replacement therapies for stimulant dependence on inhibitory control in cocaine abusers. Am J Drug Alcohol Abuse 2008;34:293-305. (Pubitemid 351572454)
55. Fox BS, Kantak KM, Edwards MA, et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nat Med 1996;2:1129-1132 (Pubitemid 26338633)
56. Fox BS. Development of a therapeutic vaccine for the treatment of cocaine addiction. Drug Alcohol Depend 1997;48:153-158 (Pubitemid 27526021)
57. Heading CE. TA-CD. Xenova. IDrugs 2002;5:1070-1074
58. Meijler MM, Matsushita M, Wirsching P, Janda KD. Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol 2004;1:77-89.
59. Kantak KM. Anti-cocaine vaccines: antibody protection against relapse. Expert Opin Pharmacother 2003;4:213-218 (Pubitemid 36240460)
60. Kosten TR, Rosen M, Bond J, et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002;20:1196-204. (Pubitemid 34135957)
61. Martell BA, Mitchell E, Poling J, Gonsai K, Kosten TR. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol Psychiatry 2005;58:158-164 (Pubitemid 41008133)